IL-1β and IL-18: Inflammatory markers or mediators of hypertension?

British Journal of Pharmacology

Volumn 171, Issue 24, 2014, Pages 5589-5602

  Krishnan, S M ^a   Sobey, C G ^a   Latz, E ^b,c,d   Mansell, A ^e   Drummond, G R ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; BELNACASAN; CANAKINUMAB; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; PATTERN RECOGNITION RECEPTOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STATIN (PROTEIN); TETRAPEPTIDE; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; CASPASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; PURINERGIC P2X RECEPTOR ANTAGONIST;

BLOOD VESSEL WALL; CHRONIC INFLAMMATION; CINCA SYNDROME; CRYSTAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TARGETING; ENZYME ACTIVATION; EPILEPSY; GOUT; HEPATITIS C; HOST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOCYTE; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD VESSEL; IMMUNOLOGY; KIDNEY; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOMARKERS; BLOOD VESSELS; CASPASE 1; CASPASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INFLAMMASOMES; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-18; INTERLEUKIN-1BETA; KIDNEY; PURINERGIC P2X RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 84911427534     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12876     Document Type: Review

References (154)

1. Ala Y, Palluy O, Favero J, Bonne C, Modat G, Dornand J, (1992). Hypoxia/reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production. Effects of free radical scavengers. Agents Actions 37: 134-139.
2. Albert MA, Danielson E, Rifai N, Ridker PM, (2001). Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol 170: 1582-1606.
6. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
7. Araujo M, Wilcox CS, (2014). Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal 20: 74-101.
8. Arend WP, Malyak M, Guthridge CJ, Gabay C, (1998). Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16: 27-55.
9. Arend WP, Palmer G, Gabay C, (2008). IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223: 20-38.
10. Bauernfeind F, Bartok E, Rieger A, Franchi L, Núñez G, Hornung V, (2011). Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 187: 613-617.
11. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. (2009). Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183: 787-791.
12. Bautista LE, (2003). Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 17: 223-230.
13. Boos CJ, Lip GY, (2006). Is hypertension an inflammatory process? Curr Pharm Des 12: 1623-1635.
14. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E, (2000). Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 35: 549-555.
15. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, (2006). Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37: 1503-1507.
16. Boulbou MS, Koukoulis GN, Makri ED, Petinaki EA, Gourgoulianis KI, Germenis AE, (2005). Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol 98: 39-44.
17. Briasoulis A, Agarwal V, Valachis A, Messerli FH, (2013). Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich) 15: 310-320.
18. Briones A, Salaices M, Vila E, (2005). Ageing alters the production of nitric oxide and prostanoids after IL-1beta exposure in mesenteric resistance arteries. Mech Ageing Dev 126: 710-721.
19. Cahill CM, Rogers JT, (2008). Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 283: 25900-25912.
20. Carroll WA, Donnelly-Roberts D, Jarvis MF, (2009). Selective P2X(7) receptor antagonists for chronic inflammation and pain. Purinergic Signal 5: 63-73.
21. Chamberlain J, Francis S, Brookes Z, Shaw G, Graham D, Alp NJ, et al. (2009). Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS ONE 4: e5073.
22. Chan C, Moore J, Budzyn K, Guida E, Diep H, Vinh A, et al. (2012). Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension 60: 1207-1212.
23. Chan EC, Datla SR, Dilley R, Hickey H, Drummond GR, Dusting GJ, (2007). Adventitial application of the NADPH oxidase inhibitor apocynin in vivo reduces neointima formation and endothelial dysfunction in rabbits. Cardiovasc Res 75: 710-718.
24. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, et al. (2006). Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281: 15099-15109.
25. Chen H, Lu ZZ, Wei H, Han C, (1997). Induction of ICE and inhibition of c-fos, jun D and zif 268 in 12-month old spontaneously hypertensive rats. Life Sci 61: PL27-PL31.
26. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, et al. (2002). Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 34: 451-461.
27. Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P, (2007). Inflammatory caspases: targets for novel therapies. Curr Pharm Des 13: 367-385.
28. Cruz CM, Rinna A, Forman HJ, Ventura AL, Persechini PM, Ojcius DM, (2007). ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem 282: 2871-2879.
29. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC, (1997). Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med 129: 300-308.
30. Davaro F, Forde SD, Garfield M, Jiang Z, Halmen K, Tamburro ND, et al. (2014). 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1beta interferes with mature IL-1beta signaling. J Biol Chem 289: 16214-16222.
31. Davis BK, Ting JP, (2010). NLRP3 has a sweet tooth. Nat Immunol 11: 105-106.
32. De Nardo D, Latz E, (2011). NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 32: 373-379.
33. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP, (2002). Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 40: 611-617.
34. Dewberry R, Holden H, Crossman D, Francis S, (2000). Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 20: 2394-2400.
35. Dinarello C, Novick D, Kim S, Kaplanski G, (2013). Interleukin-18 and IL-18 binding protein. Front Immunol 4: 289.
36. Dinarello CA, (1996). Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
37. Dinarello CA, (2002). The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 (5 Suppl. 27): S1-S13.
38. Donnelly-Roberts DL, Jarvis MF, (2007). Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151: 571-579.
39. Dörffel Y, Lätsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, et al. (1999). Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34: 113-117.
40. Dorfmuller P, Perros F, Balabanian K, Humbert M, (2003). Inflammation in pulmonary arterial hypertension. Eur Respir J 22: 358-363.
41. Dorrance A, (2007). Interleukin 1-beta (IL-1beta) enhances contractile responses in endothelium-denuded aorta from hypertensive, but not normotensive, rats. Vascul Pharmacol 47: 160-165.
42. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J, (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677.
43. Drummond GR, Selemidis S, Griendling KK, Sobey CG, (2011). Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471.
44. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361.
45. Feig DI, Soletsky B, Johnson RJ, (2008). Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300: 924-932.
46. Fleischmann R, Stern R, Iqbal I, (2004). Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 4: 1333-1344.
47. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U, (2002). Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 195: 245-257.
48. Gordon S, (2002). Pattern recognition receptors: doubling up for the innate immune response. Cell 111: 927-930.
49. Gu J-W, Tian N, Shparago M, Tan W, Bailey A, Manning R, (2006). Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 291: R1817-R1824.
50. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M, (2009). Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 60: 3642-3650.
51. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. (2007). Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460.
52. Haig A, (1889). On uric acid and arterial tension. Br Med J 1: 288-291.
53. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865.
54. Haller H, Park JK, Dragun D, Lippoldt A, Luft FC, (1997). Leukocyte infiltration and ICAM-1 expression in two-kidney one-clip hypertension. Nephrol Dial Transplant 12: 899-903.
55. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
56. Januzzi J, (2013). ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 6: 493-500.
57. Jha S, Ting JP, (2009). Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J Immunol 183: 7623-7629.
58. Ji X, Naito Y, Hirokawa G, Weng H, Hiura Y, Takahashi R, et al. (2012a). P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 35: 173-179.
59. Ji X, Naito Y, Weng H, Endo K, Ma X, Iwai N, (2012b). P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal Physiol 303: F1207-F1215.
60. Jimenez-Altayo F, Briones AM, Giraldo J, Planas AM, Salaices M, Vila E, (2006). Increased superoxide anion production by interleukin-1beta impairs nitric oxide-mediated relaxation in resistance arteries. J Pharmacol Exp Ther 316: 42-52.
61. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, et al. (1992). Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474.
62. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ, (2002). Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40: 2117-2121.
63. Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, et al. (2009). Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60: 3651-3662.
64. Kahlenberg JM, Dubyak GR, (2004). Differing caspase-1 activation states in monocyte versus macrophage models of IL-1beta processing and release. J Leukoc Biol 76: 676-684.
65. Kaminski RM, Rogawski MA, Klitgaard H, (2014). The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurother 11: 385-400.
66. Kanneganti TD, Lamkanfi M, Nunez G, (2007). Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549-559.
67. Karaoglan A, Kaya E, Akdemir O, Sagmanligil A, Bilguvar K, Cirakoglu B, et al. (2008). Neuroprotective effects of Ac.YVAD.cmk on experimental spinal cord injury in rats. Surg Neurol 69: 561-567.
68. Kojima S, Negishi Y, Tsukimoto M, Takenouchi T, Kitani H, Takeda K, (2014). Purinergic signaling via P2X receptor mediates IL-1beta production in Kupffer cells exposed to silica nanoparticle. Toxicology 321C: 13-20.
69. Kubo T, Kihara M, (1988). Evidence of N-methyl-D-aspartate receptor-mediated modulation of the aortic baroreceptor reflex in the rat nucleus tractus solitarii. Neurosci Lett 87: 69-74.
70. Kuemmerle-Deschner JB, Haug I, (2013). Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis 5: 315-329.
71. Labow M, Shuster D, Zetterstrom M, Nunes P, Terry R, Cullinan EB, et al. (1997). Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 59: 2452-2461.
72. Lamkanfi M, Dixit VM, (2014). Mechanisms and functions of inflammasomes. Cell 157: 1013-1022.
73. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. (2005). Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111: 2356-2363.
74. Latz E, (2010). NOX-free inflammasome activation. Blood 116: 1393-1394.
75. Lee D, Leite R, Fleming C, Pollock J, Webb R, Brands M, (2004). Hypertensive response to acute stress is attenuated in interleukin-6 knockout mice. Hypertension 44: 259-263.
76. Lee D, Sturgis L, Labazi H, Osborne J, Fleming C, Pollock J, et al. (2006). Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290: H935-H940.
77. Levy BI, (2004). Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109: 8-13.
78. Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP, (2005). Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 355: 131-136.
79. Liao PC, Chao LK, Chou JC, Dong WC, Lin CN, Lin CY, et al. (2013). Lipopolysaccharide/adenosine triphosphate-mediated signal transduction in the regulation of NLRP3 protein expression and caspase-1-mediated interleukin-1beta secretion. Inflamm Res 62: 89-96.
80. Loughrey JP, Laffey JG, Moore BJ, Lynch F, Boylan JF, McLoughlin P, (2003). Interleukin-1 beta rapidly inhibits aortic endothelium-dependent relaxation by a DNA transcription-dependent mechanism. Crit Care Med 31: 910-915.
81. Lu X, Kakkar V, (2014). Inflammasome and atherogenesis. Curr Pharm Des 20: 108-124.
82. MacKenzie SH, Schipper JL, Clark AC, (2010). The potential for caspases in drug discovery. Curr Opin Drug Discov Devel 13: 568-576.
83. Madej A, Okopien B, Kowalski J, Haberka M, Herman ZS, (2005). Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep 57: 878-881.
84. Madhur M, Lob H, McCann L, Iwakura Y, Blinder Y, Guzik T, et al. (2010). Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55: 500-507.
85. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
86. Martinon F, Tschopp J, (2004). Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574.
87. Martinon F, Tschopp J, (2007). Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14: 10-22.
88. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J, (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
89. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. (2001). Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106.
90. Meissner F, Molawi K, Zychlinsky A, (2008). Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol 9: 866-872.
91. Mertens M, Singh JA, (2009). Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36: 1118-1125.
92. Mervaala EM, Müller DN, Park JK, Schmidt F, Lohn M, Breu V, et al. (1999). Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33 (1 Pt 2): 389-395.
93. Miller A, Liew F, (2011). The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease. Pharmacol Ther 131: 179-186.
94. Mills K, Dungan L, Jones S, Harris J, (2013). The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 93: 489-497.
95. Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M, (2009). Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract 83: 190-199.
96. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, et al. (2000). NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35 (1 Pt 2): 193-201.
97. Nakamura S, Otani T, Okura R, Ijiri Y, Motoda R, Kurimoto M, et al. (2000). Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia 14: 1052-1059.
98. Omi T, Kumada M, Kamesaki T, Okuda H, Munkhtulga L, Yanagisawa Y, et al. (2006). An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur J Hum Genet 14: 1295-1305.
99. O'Neill LA, (2002). Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. Curr Top Microbiol Immunol 270: 47-61.
100. Palatini P, (2001). Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep 3 (Suppl. 1): S3-S9.
101. Pauletto P, Rattazzi M, (2006). Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 21: 850-853.
102. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
103. Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T, (2001). Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 31: 31-36.
104. Pei C, Barbour M, Fairlie-Clarke K, Allan D, Mu R, Jiang H-R, (2014). Emerging role of interleukin-33 in autoimmune diseases. Immunology 141: 9-17.
105. Petrilli V, Dostert C, Muruve DA, Tschopp J, (2007). The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19: 615-622.
106. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, et al. (2009). Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 106: 14948-14953.
107. Probstfield JL, O'Brien KD, (2010). Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 105 (1 Suppl.): 10A-20A.
108. Rabkin SW, (2009). The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 6: 192-199.
109. Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M, (2000). Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci 20: 4398-4404.
110. Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R, (2001). ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 10: 1207-1209.
111. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, et al. (2002). Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22: 1194-1199.
112. Ridker PM, Thuren T, Zalewski A, Libby P, (2011). Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162: 597-605.
113. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. (2012). Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126: 2739-2748.
114. Riteau N, Baron L, Villeret B, Guillou N, Savigny F, Ryffel B, et al. (2012). ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. Cell Death Dis 3: e403.
115. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ, (2004). Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616.
116. Rodriguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ, (2012). Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol 39: 96-103.
117. Ross R, (1999). Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
118. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J, (2001). Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 158: 1743-1756.
119. Schroder K, Tschopp J, (2010a). The inflammasomes. Cell 140: 821-832.
120. Schroder K, Zhou R, Tschopp J, (2010b). The NLRP3 inflammasome: a sensor for metabolic danger? Science 327: 296-300.
121. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, et al. (2003). Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31-38.
122. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA, (2001). IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 98: 13249-13254.
123. Sims JE, (2002). IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 14: 117-122.
124. Sirtori CR, (2014). The pharmacology of statins. Pharmacol Res 88C: 3-11.
125. Sriramula S, Cardinale J, Francis J, (2013). Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. PLoS ONE 8: e63847.
126. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP, (2007). Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 49: 792-798.
127. Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, et al. (2005). Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett 99: 30-35.
128. Suzuki H, Sozen T, Hasegawa Y, Chen W, Zhang JH, (2009). Caspase-1 inhibitor prevents neurogenic pulmonary edema after subarachnoid hemorrhage in mice. Stroke 40: 3872-3875.
129. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J, (2003). Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900.
130. Thomassen E, Bird TA, Renshaw BR, Kennedy MK, Sims JE, (1998). Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res 18: 1077-1088.
131. Touyz RM, Briones AM, (2011). Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 34: 5-14.
132. Touyz RM, Schiffrin EL, (2004). Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122: 339-352.
133. Touyz RM, Wu XH, He G, Salomon S, Schiffrin EL, (2002). Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 39 (2 Pt 2): 479-485.
134. Trautmann A, (2009). Extracellular ATP in the immune system: more than just a 'danger signal'. Sci Signal 2: e6.
135. Tschopp J, Schroder K, (2010). NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10: 210-215.
136. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. (2001). Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104: 376-379.
137. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, et al. (2012). Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol 303: H282-H296.
138. Van Bortel LM, (2005). What does intima-media thickness tell us? J Hypertens 23: 37-39.
139. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, et al. (2003). Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 23: 8692-8700.
140. Volonté C, Apolloni S, Skaper SD, Burnstock G, (2012). P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets 11: 705-721.
141. Vonend O, Turner C, Chan C, Loesch A, Dell'Anna G, Srai K, et al. (2004). Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 66: 157-166.
142. Wang Q, Zuo X-R, Wang Y-Y, Xie W-P, Wang H, Zhang M, (2013). Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats. Vascul Pharmacol 58: 71-77.
143. Ward HJ, (1998). Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352: 670-671.
144. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. (2001). HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450-1457.
145. Weir MR, Dzau VJ, (1999). The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12 (12 Pt 3): 205S-213S.
146. Wen H, Ting J, O'Neill L, (2012). A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 13: 352-357.
147. WHO (2013). The top 10 causes of death Vol. 2014: World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed 2/3/2014).
148. Wolf BB, Green DR, (1999). Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274: 20049-20052.
149. Wu B, Ma Q, Khatibi N, Chen W, Sozen T, Cheng O, et al. (2010). Ac-YVAD-CMK decreases blood-brain barrier degradation by inhibiting caspase-1 activation of interleukin-1beta in intracerebral hemorrhage mouse model. Transl Stroke Res 1: 57-64.
150. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, et al. (2005). Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 25: 1458-1462.
151. Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, et al. (2009). NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284: 12762-12771.
152. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, et al. (2012). Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 59: 136-144.
153. Zhou MS, Schulman IH, Raij L, (2010a). Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens 28: 527-535.
154. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J, (2010b). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140.